Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Perfuse-Therapeutics"

2 News Found

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics
News | May 07, 2026

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy

Bayer seals $300 million Perfuse deal
News | June 18, 2026

Bayer seals $300 million Perfuse deal

Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline

Upcoming E-conference
June 19, 2026 The Future of Clinical Research in India: Can India Become a Global Trial Hub?
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Moderna reshapes leadership and ops model as it pushes into oncology, rare disease

Siegfried opens major API manufacturing facility in Germany

Pharma PLI scheme attracted Rs. 42,694 crore investments, created 1.13 lakh jobs in 6 years: Govt

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

Packaging